
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 18 |
| Proteolysis-targeting chimeras (PROTAC) | 3 |
| Chemical drugs | 2 |
| Peptibody | 1 |
| Biosimilar | 1 |
Target |
Mechanism PDL1 inhibitors [+1] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date30 Apr 2024 |
Target |
Mechanism L-type calcium channel blockers |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date01 Aug 2008 |
Start Date24 Aug 2026 |
Sponsor / Collaborator |
Start Date27 Mar 2026 |
Sponsor / Collaborator |
Start Date18 Mar 2026 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Alprostadil ( EP1 ) | Arterial Occlusive Diseases More | Approved |
Lidocaine ( SCNA ) | Diabetic peripheral neuropathic pain More | Approved |
Flurbiprofen Axetil ( COXs ) | Cancer Pain More | Approved |
Ropivacaine Hydrochloride ( SCNA ) | Pain, Postoperative More | Phase 3 |
Flurbiprofen ( COXs ) | Osteoarthritis, Knee More | Phase 3 |





